Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 21.5% – Should You Buy?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) rose 21.5% during mid-day trading on Monday . The stock traded as high as $8.15 and last traded at $8.01. Approximately 30,862,008 shares traded hands during trading, an increase of 149% from the average daily volume of 12,371,136 shares. The stock had previously closed at $6.59.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on RXRX. Needham & Company LLC reissued a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday. Jefferies Financial Group reduced their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Finally, Leerink Partners reduced their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $9.25.

Recursion Pharmaceuticals Stock Performance

The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock’s 50 day moving average price is $6.67 and its two-hundred day moving average price is $7.29. The firm has a market capitalization of $2.24 billion, a PE ratio of -4.88 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $26.08 million for the quarter, compared to analysts’ expectations of $12.62 million. During the same period last year, the business earned ($0.43) earnings per share. The company’s revenue for the quarter was up 147.6% on a year-over-year basis. On average, equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the transaction, the chief financial officer now owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. The trade was a 0.99 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Christopher Gibson sold 20,000 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total transaction of $123,200.00. Following the completion of the transaction, the chief executive officer now owns 762,656 shares in the company, valued at $4,697,960.96. This represents a 2.56 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 119,235 shares of company stock valued at $802,988. Company insiders own 15.75% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors have recently modified their holdings of RXRX. Allspring Global Investments Holdings LLC bought a new stake in shares of Recursion Pharmaceuticals during the 3rd quarter valued at about $25,000. Farther Finance Advisors LLC grew its position in Recursion Pharmaceuticals by 176.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after purchasing an additional 4,091 shares during the last quarter. KBC Group NV grew its position in Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after purchasing an additional 3,377 shares during the last quarter. Amalgamated Bank lifted its stake in shares of Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after acquiring an additional 2,459 shares during the period. Finally, San Luis Wealth Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 3rd quarter worth approximately $69,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.